Brief: Advaxis Announces Updated Positive Clinical And Biomarker Data From Ongoing Phase 1/2 Adxs-503 Trial In NSCLC

Ayala Pharmaceuticals

14/05/2020 13:24

May 14 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS ANNOUNCES UPDATED POSITIVE CLINICAL AND BIOMARKER
DATA
FROM ONGOING PHASE 1/2 ADXS-503 TRIAL IN NSCLC
    * ADVAXIS INC - POSITIVE PRELIMINARY IMMUNOGENICITY DATA
WITH CD8+
T CELLS GENERATED IN ALL OF FIRST SEVEN PATIENTS EVALUATED FOR
ADXS-503 ANTIGENS
    * ADVAXIS INC - SUSTAINED CLINICAL BENEFIT SEEN IN PATIENTS
TREATED WITH ADXS-503 IN COMBINATION WITH KEYTRUDA® AFTER 16
WEEKS

Source text for Eikon:  ID:nGNX81tSLJ 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))